 |
Samsung BioLogics (photo = Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Samsung BioLogics made an announcement on the 4th that its contract for consignment production of drugs worth 92.8 billion won signed with global pharmaceutical company MSD Switzerland has increased to 247.3 billion won.
Samsung BioLogics said, "It is a change in the amount due to the success of commercialization of customer products." The contract is a 276.8 billion won contract signed by Samsung BioLogics with MSD in 2022 for consignment production of medicines and a new individual contract. The contracted product is closed to the public.
The contract period is from the 1st of last month to December 31st, 2032. The contract termination date is subject to change according to the agreement between the two companies.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
